A securities class action lawsuit has been filed against Boston Scientific and certain officers on behalf of investors who purchased the company’s securities between July 23, 2025 and February 3, 2026. The complaint alleges the defendants made materially false or misleading statements about the sustainability of projected fiscal 2025 growth, particularly in the U.S. electrophysiology segment. It also alleges the company faced adverse trends affecting procedure volumes, competitive pressures, and regulatory and reimbursement headwinds impacting that segment. The filing states investors have until May 4, 2026 to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181200PRIMZONEFULLFEED9672290) on March 18, 2026, and is solely responsible for the information contained therein.